Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study.

ABSTRACT:

Background

Inhibition of the programmed death ligand 1, programmed death 1 pathway has been successfully used for treatment of multiple advanced adult cancers. However, its use in pediatric osteosarcoma is still in its infancy. In this study, we investigated programmed death ligand 1 and other checkpoint molecules' expression to determine the potential usefulness as targets for drug therapy.

Methods

We incubated human wild-type osteosarcoma cells with incremental concentrations of doxorubicin to create a doxorubicin-resistant cell line. Matrigel in vitro invasion assays were used to compare invasiveness. Comparative programmed death ligand 1 expression was evaluated by Western blot assays. An immuno-oncology checkpoint protein panel was used to compare concentrations

SUBMITTER: Skertich NJ 

PROVIDER: S-EPMC8346678 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature